PHARMACOECONOMICS

Eradication of Helicobacter pylori offers the potential of cost saving s in combination with better outcomes over intermittent or maintenance therapy of duodenal ulcer disease, Treatment regimes that give a high er eradication rate are cost-effective despite higher costs. In the sa me way, an early eradication policy is more cost-effective than delaye d management, Studies comparing empirical therapy with initial endosco py show very different expected costs for patient management and the c onclusions are conflicting.